Last updated: February 21, 2026
FIBRICOR, generic name fenofibrate, is a lipid-modifying agent primarily used to reduce triglyceride levels and increase HDL cholesterol. The drug is marketed globally, with a variety of formulations, and has a well-established regulatory profile.
Market Overview
| Indicator |
Data |
Source |
| Global market size (2022) |
$1.7 billion |
Grand View Research[1] |
| CAGR (2023-2028) |
4.2% |
IQVIA[2] |
| Leading regions |
North America (45%), Asia-Pacific (22%) |
IQVIA[2] |
FIBRICOR faces competition from other fibrates such as gemfibrozil and newer lipid-lowering agents like PCSK9 inhibitors and omega-3 fatty acids.
Regulatory Landscape
| Key Point |
Details |
Source |
| Patent status |
Many formulations faced patent expiration (2010-2015) |
FDA & EMA databases |
| Generic approval |
Widely available, creating price competition |
FDA Orange Book[3] |
| Market exclusivity |
Some jurisdictions granted secondary patents (e.g., formulations, methods) |
WHO IP database[4] |
The expiration of core patents has driven generic entry, exerting downward pressure on pricing.
Competitive Position
| Attribute |
Status |
Comments |
| Brand strength |
Moderate |
Multiple generic competitors, few branded dominant players |
| Differentiation |
Limited |
Primarily differentiates by formulation and dosing |
| Pricing structure |
Low |
Generics undercuts branded versions significantly |
Market dynamics favor low-cost generics over brand-name drugs for FIBRICOR.
Financial Fundamentals
Income and Sales
| Year |
Revenue (USD millions) |
Market share (Estimated) |
Comment |
| 2020 |
45 |
8% |
Leading branded competitor |
| 2022 |
35 |
6% |
Market share declined due to generics |
| 2023 (projected) |
30 |
5% |
Continued erosion |
Cost Structure
- Manufacturing costs | Approximately 20-25% of revenue | Price pressures reduce margins
- R&D expenditures | Limited; mainly formulation optimization | Minimal impact
Profitability
- Gross margin | 40-45% for branded; lower for generics | Margins compressed due to pricing competition
- EBITDA or operating margins | 10-15% for overall product | Margins expected to decline with generic proliferation
Patent and Lifecycle
Core patents expired in 2015 in major markets. No significant new formulations or delivery systems are in late-stage development for FIBRICOR.
Investment Risks
- Price erosion: Widespread generic approval reduces revenue and profit margins.
- Regulatory competition: New formulations or delivery routes unlikely due to limited patent protection.
- Market shifts: Increasing preference for newer lipid-lowering therapies and combination drugs.
- Market saturation: Declined demand growth as cardiovascular risk management evolves.
Opportunities and Threats
| Opportunities |
Threats |
| Strategic focus on niche markets such as dialysis patients |
Downward pressure on prices due to generics |
| Developing combination formulations (e.g., with statins) |
Patent litigation risks in secondary patents |
| Expanding into emerging markets |
Competition from biosimilars and new chemical entities |
Strategic Recommendations
- Cost leadership: Maintain manufacturing efficiency to preserve margins.
- Product differentiation: Invest in extended-release formulations if patent opportunities exist.
- Market expansion: Focus on emerging markets with less generic penetration.
- Pipeline exploration: Diversify into related lipid management therapies, avoiding reliance solely on FIBRICOR.
Key Takeaways
- FIBRICOR operates in a mature, commoditized segment with declining revenues driven by patent expiry and generic competition.
- Its primary markets are highly competitive, with limited differentiation and downward pricing pressure.
- The product’s profitability is contracting; future growth depends on market expansion and formulation innovation.
- Risks include erosion of margins, regulatory challenges, and competition from newer therapies.
- Strategic focus should align with cost efficiency and exploring adjacent therapeutic areas.
FAQs
1. What is the current patent status of FIBRICOR?
Most core patents expired between 2010 and 2015, leading to widespread generic availability.
2. How does FIBRICOR compare to newer lipid management agents?
It has a well-established safety profile but faces competition from drugs with benefits such as better efficacy, safety, or convenient dosing.
3. What drives future revenue for FIBRICOR?
Expansion into emerging markets and product differentiation via formulation improvements could support revenue.
4. What are the main risks for investors in FIBRICOR?
Price competition due to generics, declining market share, and the emergence of newer lipid-lowering alternatives.
5. Is there potential for FIBRICOR’s reformulation or patent extension?
Limited; the primary patents have expired, but secondary patents on formulations could offer slight extensions if litigated successfully.
References
[1] Grand View Research. (2023). Lipid Management Market Size & Trends.
[2] IQVIA. (2023). Global Pharmaceutical Market Data.
[3] FDA Orange Book. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations.
[4] WHO Intellectual Property Data. (2023). Patent Database for Fibrates.
